Literature DB >> 12879634

[Are statins of value in therapy of osteoporosis?].

Markus Gosch1.   

Abstract

The statins do not only lower cholesterol. They may have also many other positive effects. The effects beyond lipid reduction are called pleiotropic effects. One of the most interesting points is the relationship between the statins and osteoporosis. They may stimulate bone formation and as a consequence they may reduce the risk of fracture. In the past years several studies were published concerning this topic. A number of observational studies found a decreased incidence of fractures among patients who take statins, but other studies did not. Prospective randomized controlled studies are necessary to exclude the possibility of unmeasured confounding variables. At the moment we have not enough data to give an answer to the question, if statins are a usefull opportunity in the treatment of osteoporosis. What we know now is, that the statins may be an interesting drug in the future for the treatment of osteoporosis, although many things are unclear, such as the right dose or the duration of treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879634     DOI: 10.1046/j.1563-258x.2003.03030.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  22 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

2.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

3.  The effect of fluvastatin on parameters of bone remodeling.

Authors:  N H Bjarnason; B J Riis; C Christiansen
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

Review 4.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

5.  Use of statins and risk of fractures.

Authors:  T P van Staa; S Wegman; F de Vries; B Leufkens; C Cooper
Journal:  JAMA       Date:  2001-04-11       Impact factor: 56.272

6.  Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.

Authors:  I R Reid; W Hague; J Emberson; J Baker; A Tonkin; D Hunt; S MacMahon; N Sharpe
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

7.  Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia.

Authors:  M H Chan; T W Mak; R W Chiu; C C Chow; I H Chan; C W Lam
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

8.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.

Authors:  K A Chan; S E Andrade; M Boles; D S Buist; G A Chase; J G Donahue; M J Goodman; J H Gurwitz; A Z LaCroix; R Platt
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

9.  HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.

Authors:  Y S Chung; M D Lee; S K Lee; H M Kim; L A Fitzpatrick
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

10.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

Authors:  Julie A Pasco; Mark A Kotowicz; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson
Journal:  Arch Intern Med       Date:  2002-03-11
View more
  1 in total

Review 1.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.